Detail akcie Bavarian Nordic online

Business Summary: Bavarian Nordic A/S is a Denmark-based biotechnology company engaged in manufacturing of pharmaceutical preparations. The Company is involved in research and development innovations, production and commercialization of life-saving vaccines based on viral vectors for the delivery of antigens targeting infectious diseases. Bavarian Nordic A/S offers travel health products including cholera, rabies, tick-borne encephalitis and typhoid vaccines, as well as vaccines sold and distributed in selected markets on behalf of third parties. The Company deals with vaccines aimed at improving public health and preparedness. Bavarian Nordic A/S focuses on vaccine solutions that help address the threat of infectious diseases. The Company operates worldwide.
Financial Summary: BRIEF: For the three months ended 31 March 2024, Bavarian Nordic A/S revenues decreased 34% to DKR831.5M. Net loss totaled DKR114.5M vs. income of DKR376.4M. Revenues reflect Sale of goods - MVA-BN smallpox vaccine sale segment decrease of 59% to DKR343.8M, Sale of goods - other product sale segment decrease of 25% to DKR32.3M. Net loss reflects Administrative increase of 33% to DKR120.3M (expense).